STEM -- StemCells, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc.

STEM 16.67

+1.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (168)	1/10/1999 4:19:00 PM
From: WWS	Read Replies (1) of 805

Miljenko, glad to see you over here. I got into CTII about 2 months ago, and also into VMRX about same time, another stem cell company. I noted your concerns about ethics of CTII's use of placebo control group for its Phase II study. Since proposed study had to go through at least one (probably more) Institutional Review Boards they probably addressed your concerns. Generally approval is granted for research studies if health of placebo group is not threatened by withholding of active treatment, and also if active treatment is made available to the placebo group once study is over. Both of these conditions seem to have been met in this study. Thanks again for all the information you provided to me about possible new treatments for ovarian cancer. My friend is still doing well now, approximately 20 months post-operative (ovarian epithelial stage 4 cancer) and after standard chemo w/cisplat and tamoxifen. Bill.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next